Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

MEK2 inhibitor

DRUG CLASS:

MEK2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

NRAS mutation	Melanoma	NRAS mutation	Melanoma	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2
BRAF V600E	Glioma	BRAF V600E	Glioma	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2
MSI-L/dMMR	Colorectal Cancer	MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
BRAF mutation + MSI-L/dMMR	Colorectal Cancer	BRAF mutation + MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
NF1 mutation	Glioma	NF1 mutation	Glioma	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3
BRAF L597S	Melanoma	BRAF L597S	Melanoma	REC-4881 Sensitive: C4 – Case Studies REC-4881 Sensitive : C4	REC-4881 Sensitive: C4 – Case Studies REC-4881 Sensitive : C4
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
ESRP1-RAF1 fusion	Prostate Cancer	ESRP1-RAF1 fusion	Prostate Cancer	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D